UK-based biopharma venture studio
Three Lions BioCapital creates and invests in subsidiaries developing novel drugs for truly unmet medical needs, with each program designed from inception around pharmaceutical licensing potential.
Key features
Traditional biopharma venture capital often starts with compelling science and searches for the market later. Three Lions starts with a licensable unmet need and works backward to the product, evidence package, and partner logic.
Patent cliffs, declining R&D productivity, and a constrained IPO market are increasing demand for externally developed, licensable drug candidates. Three Lions is structured around that demand.
Each subsidiary houses one to three drug development programs selected for unmet need, scientific rationale, and licensing attractiveness.
Indication selection, candidate sourcing, diligence, and partner engagement are evaluated through a commercial licensing lens.
Centralized services and active portfolio management reduce duplicated overhead, directing more capital toward impactful development work.
WHISE, the firm's proprietary white space intelligence search engine, is an agentic AI framework that interrogates overlapping disease, target, and specialist provider datasets to identify underexploited opportunities.
Structured rubrics help surface licensing-attractive programs at a speed and scale beyond a manual business development network alone.
Recommendations such as PURSUE initiate focused diligence, from rapid AI-assisted dossiers to expert and counterparty engagement.
No fixed therapeutic area, modality, stage, or geography prevents the fund from following the strongest available opportunities.
A UK base provides access to internationally recognized development pathways and potential R&D tax credit benefits that may reduce effective program costs.
For the current Tearsheet or a conversation about the Three Lions BioCapital strategy, please contact us directly.
